Structural Heart Disease

Structural heart diseases include any issues preventing normal cardiovascular function due to damage or alteration to the anatomical components of the heart. This is caused by aging, advanced atherosclerosis, calcification, tissue degeneration, congenital heart defects and heart failure. The most commonly treated areas are the heart valves, in particular the mitral and aortic valves. These can be replaced through open heart surgery or using cath lab-based transcatheter valves or repairs to eliminate regurgitation due to faulty valve leaflets. This includes transcatheter aortic valve replacement (TAVR). Other common procedures include left atrial appendage (LAA) occlusion and closing congenital holes in the heart, such as PFO and ASD. A growing area includes transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

Real-world MitraClip data show positive 1-year outcomes

A post-approval study of Abbott’s MitraClip device showed positive one-year results for the first 2,000 patients entered into the national Transcatheter Valve Therapy registry, according to late-breaking science presented April 26 at SCAI 2018 in San Diego.

Thumbnail

Researchers develop first tool to predict readmission rates after TAVR

The first-ever risk score for predicting 30-day readmission rates in patients undergoing transcatheter aortic valve replacement (TAVR) can be easily folded into electronic medical records and inform perioperative care decisions, researchers reported at the Society for Cardiovascular Angiography and Interventions 2018 Scientific Sessions.

Two-Year Feasibility Study Results Encouraging with Medtronic Harmony(TM) Transcatheter Pulmonary Valve

DUBLIN and SAN DIEGO — April 26, 2018 — Medtronic plc (NYSE: MDT) today announced two-year outcomes for the Harmony(TM) Transcatheter Pulmonary Valve (TPV) from its early feasibility study. Presented at the Society for Cardiovascular Angiography and Interventions (SCAI) 41st Annual Scientific Sessions, data from 18 patients followed out to two years revealed the Harmony TPV showed solid valve function and no paravalvular leak (PVL).

TMVR linked to high early mortality, persistent improvement among survivors

Transcatheter mitral valve replacement (TMVR) is associated with high rates of mortality in patients with severe mitral annular calcification, but survivors show significant improvements in heart-related symptoms.

Thumbnail

Researchers propose tweak to pulse oximetry testing for CHD

Modifying the American Academy of Pediatrics’ (AAP) critical congenital heart disease (CCHD) screening algorithm to include one repeat pulse oximetry test instead of two could identify more infants with other serious diseases that require attention, according to a study published online April 24 in Pediatrics.

Thumbnail

CHD patients have 8 times the risk of hemorrhagic stroke at young age

Children and young adults who were born with congenital heart disease (CHD) have an eight-fold risk of intracerebral hemorrhage (ICH) when compared to the general population, according to a Swedish study published online April 6 in Stroke. However, the absolute risk of hemorrhagic stroke remained low for both groups.

Thumbnail

Viva la France: TAVR procedures soar, mortality rates dip between 2007-2015 in nationwide survey

A country-wide examination of data in France showed a marked increase in transcatheter aortic valve replacement (TAVR) procedures, in addition to reduction in in-hospital mortality for all AVR subsets.

Thumbnail

Severe mitral stenosis tied to worse outcomes post-TAVR

About 3 percent of patients undergoing transcatheter aortic valve replacement (TAVR) also have severe mitral stenosis and are at a greater risk of long-term adverse events, researchers reported in JACC: Cardiovascular Interventions.

Around the web

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.